HLA genotypes and rubella vaccine immune response: additional evidence
- PMID: 24837503
- PMCID: PMC4124933
- DOI: 10.1016/j.vaccine.2014.04.091
HLA genotypes and rubella vaccine immune response: additional evidence
Abstract
Recent population-based studies have demonstrated the genetic heritability of rubella vaccine response and assessed that the HLA system may explain about 20% of the inter-individual variance in humoral immune response to this vaccine. Our earlier studies compared HLA allelic associations with rubella vaccine-specific antibodies between two smaller cohorts of healthy Rochester, MN, children (346 and 396 subjects) after two doses of rubella-containing vaccine. This study found that specific HLA alleles were consistently associated with rubella-specific antibody titers (B*27:05, DPA1*02:01, and DPB1*04:01 alleles). The current study examined HLA associations in an independent larger cohort of 1012 healthy San Diego, CA, subjects (age 19-40 years) after rubella vaccine in order to replicate our previous findings in the Rochester subjects. Two HLA associations of comparable magnitudes were consistently observed between B*27:05 (median NT50 Rochester cohort 48.9, p=0.067; San Diego cohort 54.8, p=0.047) and DPB1*04:01 (median NT50 Rochester cohort 61.6, p<0.001; San Diego cohort 70.8, p=0.084) alleles and rubella virus-neutralizing antibody titers. Additional HLA alleles resulted in consistent effects on IL-6 production in both cohorts, but did not meet criteria for statistical significance. Our data suggest these HLA alleles play a role in rubella vaccine-induced immunity and provide the basis for future studies that may explain the mechanism(s) by which these HLA polymorphisms affect immune responses to rubella vaccine.
Keywords: Cytokines; HLA antigens; Neutralizing antibodies; Rubella vaccine.
Copyright © 2014 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Dr. Poland is the chair of a Safety Evaluation Committee for novel non-rubella investigational vaccine trials being conducted by Merck Research Laboratories. Dr. Poland offers consultative advice on vaccine development to Merck & Co. Inc., CSL Biotherapies, Avianax, Sanofi Pasteur, Dynavax, Novartis Vaccines and Therapeutics, PAXVAX Inc, and Emergent Biosolutions. Drs. Poland and Ovsyannikova hold two patents related to measles and vaccinia peptide research. These activities have been reviewed by the Mayo Clinic Conflict of Interest Review Board and are conducted in compliance with Mayo Clinic Conflict of Interest policies. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and was conducted in compliance with Mayo Clinic Conflict of Interest policies.
Similar articles
-
Replication of rubella vaccine population genetic studies: validation of HLA genotype and humoral response associations.Vaccine. 2009 Nov 16;27(49):6926-31. doi: 10.1016/j.vaccine.2009.08.109. Epub 2009 Sep 15. Vaccine. 2009. PMID: 19761839 Free PMC article.
-
Polymorphisms in HLA-DPB1 are associated with differences in rubella virus-specific humoral immunity after vaccination.J Infect Dis. 2015 Mar 15;211(6):898-905. doi: 10.1093/infdis/jiu553. Epub 2014 Oct 6. J Infect Dis. 2015. PMID: 25293367 Free PMC article.
-
Extended LTA, TNF, LST1 and HLA gene haplotypes and their association with rubella vaccine-induced immunity.PLoS One. 2010 Jul 27;5(7):e11806. doi: 10.1371/journal.pone.0011806. PLoS One. 2010. PMID: 20668555 Free PMC article.
-
The contribution of HLA class I antigens in immune status following two doses of rubella vaccination.Hum Immunol. 2004 Dec;65(12):1506-15. doi: 10.1016/j.humimm.2004.07.001. Hum Immunol. 2004. PMID: 15603879
-
HLA alleles associated with the adaptive immune response to smallpox vaccine: a replication study.Hum Genet. 2014 Sep;133(9):1083-92. doi: 10.1007/s00439-014-1449-x. Epub 2014 Jun 1. Hum Genet. 2014. PMID: 24880604 Free PMC article.
Cited by
-
Searching for the human genetic factors standing in the way of universally effective vaccines.Philos Trans R Soc Lond B Biol Sci. 2015 Jun 19;370(1671):20140341. doi: 10.1098/rstb.2014.0341. Philos Trans R Soc Lond B Biol Sci. 2015. PMID: 25964463 Free PMC article. Review.
-
Current Challenges in Vaccinology.Front Immunol. 2020 Jun 25;11:1181. doi: 10.3389/fimmu.2020.01181. eCollection 2020. Front Immunol. 2020. PMID: 32670279 Free PMC article. Review.
-
Intralymphatic glutamic acid decarboxylase administration in type 1 diabetes patients induced a distinctive early immune response in patients with DR3DQ2 haplotype.Front Immunol. 2023 Feb 2;14:1112570. doi: 10.3389/fimmu.2023.1112570. eCollection 2023. Front Immunol. 2023. PMID: 36817467 Free PMC article. Clinical Trial.
-
Host genetics and infectious disease: new tools, insights and translational opportunities.Nat Rev Genet. 2021 Mar;22(3):137-153. doi: 10.1038/s41576-020-00297-6. Epub 2020 Dec 4. Nat Rev Genet. 2021. PMID: 33277640 Free PMC article. Review.
-
Seroprevalence and durability of rubella virus antibodies in a highly immunized population.Vaccine. 2019 Jun 27;37(29):3876-3882. doi: 10.1016/j.vaccine.2019.05.049. Epub 2019 May 21. Vaccine. 2019. PMID: 31126859 Free PMC article.
References
-
- Plotkin SA. The history of rubella and rubella vaccination leading to elimination. Clin Infect Dis. 2006;43(Suppl 3):S164–S8. - PubMed
-
- LeBaron CW, Forghani B, Matter L, Reef SE, Beck C, Bi D, et al. Persistence of rubella antibodies after 2 doses of measles-mumps-rubella vaccine. J Infect Dis. 2009;200(6):888–99. - PubMed
-
- Baer G, Bonhoeffer J, Schaad UB, Heininger U. Seroprevalence and immunization history of selected vaccine preventable diseases in medical students. Vaccine. 2005;23(16):2016–20. - PubMed
-
- Tan PL, Jacobson RM, Poland GA, Jacobsen SJ, Pankratz SV. Twin studies of immunogenicity - determining the genetic contribution to vaccine failure. Vaccine. 2001;19:2434–9. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials